Warnings ordered on testosterone drugs like Lilly’s Axiron
Makers of testosterone drugs must change the products’ labels to clarify that they are approved for only certain disorders, not to help men deal with aging, U.S. regulators said.
Pharmaceutical
Articles
Bill aimed at reducing meth problems advances
The Indiana Senate passed a bill 46-3 on Tuesday that would make it more difficult for criminals to purchase products used in the production of meth.
Lilly to delay U.S., EU approval of basal insulin
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
Feds finally end probe into Lilly bribery allegations
The U.S. Department of Justice told Lilly last month its investigation was over—more than a year after the drugmaker paid $29 million to the SEC to settle related bribery allegations.
Lawmakers aim to restrict access to meth ingredients
The leaders of Indiana communities hit hard by methamphetamine are arguing for a state law requiring prescriptions to buy cold and allergy pills.
How Eli Lilly CEO Lechleiter pulled company out of long slide
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
Medical-marijuana bill won’t fly this session, but attitudes shift
Indiana won’t put itself on the marijuana-friendly map this year, as a medical marijuana bill authored by Democratic Sen. Karen Tallian is unlikely to go further than a committee hearing.
Novartis expects price war with Lilly over psoriasis drugs
Novartis AG is racing to establish itself in the market for new treatments for psoriasis ahead of competing drugs by Amgen Inc. and Eli Lilly and Co. in the United States.
UPDATE: Lilly says it couldn’t have made tainted Cialis
A batch of Cialis pills, purportedly made at a plant in Australia, was banned by the FDA from entering the U.S. after the pills were found to contain the active ingredient for rival drug Viagra. Cialis manufacturer Eli Lilly said it doesn’t make any drugs in Australia.
Lilly’s Cyramza gets new marketing approval
Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.
Alzheimer’s tests present dilemma of knowing the future
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Lilly rheumatoid arthritis drug meets goals in final-stage trial
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Lilly competitor claims early success with Alzheimer’s drug
Biogen Idec Inc. shares rose Tuesday after the company said its Alzheimer’s drug showed promising early results and will be quickly moved into a final-stage trial.
Lilly competitor Glaxo to shake up U.S. operations
A major drugmaker that was part of three-way multi-billion-dollar deal this year involving Eli Lilly and Co. is planning a reorganization that will include hundreds of job cuts in the United States.
Fifth person pleads guilty in Lilly warehouse heist
Prosecutors say the theft from an Eli Lilly and Co. warehouse in Connecticut involved up to $100 million in prescription drugs.
New type of cholesterol drug shows promise in study
The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.
Eli Lilly donates $12.7 million to United Way
The donation represents the giving of employees and retirees of Lilly and Elanco Animal Health in the U.S. and Puerto Rico, plus a matching contribution from the Lilly Foundation.
Lilly partner accused of putting Actos profit ahead of safety
Executives knew by 2004 that studies found links between Actos and cancer, and didn’t issue a warning until seven years later to protect billions of dollars in sales of the drug, attorney Michael Miller told a state-court jury in Philadelphia on Thursday.
Lilly to end development of lupus drug after trial failure
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
Obamacare enrollment at 7.3 million people, official says
That’s a 9-percent reduction from the government’s May estimate of 8 million, which reflected only how many people had signed up, not how many had paid and were enrolled in the coverage.